No profile data available.
Provectus Biopharmaceuticals, Inc. (PVCT) is a healthcare company in the animal healthcare items industry, based in Knoxville, United States, with about 6 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$5.51 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $22.27 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States. The company's lead molecule is rose bengal sodium, a class of bioactive synthetic small molecules halogenated xanthenes.
Provectus Biopharmaceuticals reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$22.27 million as of October 9, 2026.
Listed companies of a similar size in the same industry (animal healthcare items) include Phibro Animal Health Corporation (PAHC), ImmuCell Corporation (ICCC), Zhengye Biotechnology Holding Limited (ZYBT), VolitionRx Limited (VNRX).